Boehringer Ingelheim Human Pharma Clinical Pipeline
Selection of projects in October 2024.
Cardio-Renal-Metabolic
Obesity
GLP1/GCGR agonist
Survodutide (BI 456906)
Cardio-Renal-Metabolic
Chronic kidney disease
Aldosterone synthase inhibitor & SGLT2 inhibitor
Vicadrostat (BI 690517) & Empagliflozin
Cardio-Renal-Metabolic
Heart failure with preserved ejection fraction
Aldosterone synthase inhibitor & SGLT2 inhibitor
Vicadrostat (BI 690517) & Empagliflozin
Mental Health
Schizophrenia
Prescription digital therapeutic
CT-155 (BI 3972080)
Mental Health
Cognitive impairment associated with schizophrenia
GlyT1 inhibitor
Iclepertin (BI 425809)
Oncology
Non-small cell lung cancer
HER2 TKI
Zongertinib (BI 1810631)
Respiratory
Idiopathic pulmonary fibrosis
PDE4B inhibitor
Nerandomilast (BI 1015550)
Respiratory
Progressive pulmonary fibrosis
PDE4B inhibitor
Nerandomilast (BI 1015550)
Cardio-Renal-Metabolic
Focal Segmental Glomerulosclerosis
TRPC6 inhibitor
BI 764198
Cardio-Renal-Metabolic
Myocardial infarction
Heart disease modulator
BI 765845
Cardio-Renal-Metabolic
Metabolic Dysfunction-Associated Steatohepatitis
GLP1/GCGR agonist
Survodutide (BI 456906)
Immunology
Systemic sclerosis
sGC activator
Avenciguat (BI 685509)
Immunology
Systemic Sclerosis
PDE4B inhibitor
Nerandomilast (BI 1015550)
Immunology
Hidradenitis suppurativa
IL36R antibody
Spesolimab (BI 655130)
Immunology
Netherton syndrome
IL36R antibody
Spesolimab (BI 655130)
Immunology
Pyoderma gangrenosum
IL36R antibody
Spesolimab (BI 655130)
Oncology
Small-cell lung cancer
DLL3/CD3 T-cell engager
Obrixtamig (BI 764532)
Oncology
Extra-pulmonary neuroendocrine carcinoma
DLL3/CD3 T-cell engager
Obrixtamig (BI 764532)
Oncology
Non-small-cell lung cancer
MDM2-p53 antagonist
Brigimadlin (BI 907828)
Respiratory
Non-cystic fibrosis bronchiectasis
CatC inhibitor
BI 1291583
Respiratory
Idiopathic/progressive pulmonary fibrosis
Lysophospholipase inhibitor
BI 1819479
Retinal Health
Diabetic retinopathy
Sema3A antibody
BI 764524